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Thus in normal subjects or patients with impaired renal function injection of 40 mg. of gentamicin fails in the majority of cases to produce serum levels reaching the minimum inhibitory concentration of clinical isolates of Ps. aeruginosa. With this dose the serum level will rarely exceed the minimum inhibitory concentration by a factor of two, nor will it be maintained for half the interval between doses, though both circumstances are desirable when treating pseudomonas infections. Serum levels in patients with impaired renal function may gradually build up even on small doses, but this is an inefficient method of treatment calculated to encourage the development of resistance in a bacterial population. In three patients treated unsuccessfully the minimum inhibitory concentration of strains isolated after treatment had increased eightfold. This is the first report of resistance acquired in vivo, and it is interesting that there is a similar increase in the minimum inhibitory concentration of kanamycin, though naturally occurring resistance to kanamycin does not involve gentamicin.
Doses of 80 mg. produce more realistic peak levels-5.4 jug./ ml. in one patient, and 10.15 [g./ml. in another in whom the dose was increased during treatment. If treatment with gentamicin is contemplated initial dosage of this order, or possibly even higher, seems necessary. To avoid toxic levels, estimation of serum concentrations is necessary in patients with impaired renal function and probably in the elderly (compare streptomycin). Prolonged courses of treatment are to be avoided. If given in adequate dosage initially treatment is likely to be effective, if it is to succeed at all, in 7 to 10 days.
It is assumed in this discussion that adequate tissue levels are necessary for effective treatment, as they clearly must be for any lesion outside the urinary tract. The concentrations attained in the urine are much higher, and may suffice to overcome a urinary tract infection not involving the renal parenchyma.
The work reported is being continued as a study of the relation of serum levels to results of treatment in urinary infections, complicated and uncomplicated.
Summary
Blood concentrations were assayed in normal subjects and in patients receiving the recommended dose of gentamicin. These were often found to be lower than the usual minimum inhibitory concentration of this antibiotic for Pseudomonas aeruginosa. The resistance of the infecting strain in three patients given this dose increased during treatment. It is suggested that larger doses, controlled by blood assay, are required for satisfactory therapeutic effects.
We would like to thank Professor L. P. Garrod for his encouragement in preparing this report and our clinical colleagues for allowing us to include reports of cases under their care.
The gentamicin sulphate used was supplied as Genticin by British Schering Limited.
After parenteral administration, elimination is mainly via the kidney in normal subjects, 80-90% being recoverable in the active form in the urine; a small amount may be found in bile (Black et al., 1963) . This study was undertaken to obtain information on blood levels of gentamicin and to assess what dosage revision may be necessary in severe renal failure.
Methods
Two normal subjects and three patients with terminal renal failure were studied. The patients were maintained on chronic intermittent haemodialysis. Gentamicin was administered therapeutically to two of the patients because of Pseudomonas pyocyanea shunt-site infections and prophylactically to the third. Details of the patients and normal subjects are given in the Table. The patients were dialysed for 14 hours twice weekly .by means of a modified two-layer Kiil dialyser with cuprophane membranes (PT 150). Dialysis fluid at 400 C. was employed in a single pass system (Curtis and de Wardener, 1967) . In the 
Results
Plasma Concentration in Normal Subjects.-Ten minutes after the intravenous injection of 1.6 mg. of gentamicin per kg. body weight to the two normal subjects the plasma concentration rose to 5 and 7.5 Jug./ml. respectively. In both instances no antibiotic activity was detected in the plasma 24 hours after administration.
Plasma Concentration in Patients with Renal Failure.-After the initial intravenous administration of 0.8 mg. of gentamicin per kg. body weight to the three patients the mean plasma level at 10 minutes was 6 tig./ml., and 24 hours later it had fallen to 4.5 ttg./ml. At 48 hours the mean level was 2.0 jg./ml. On a second occasion, 72 hours later, 1.6 mg. of gentamicin per kg. body weight was given intravenously. Before this injection the mean plasma concentration of gentamicin was 1.5 ,ttg./ml. ; 10 minutes later it was 16.0 ,ug./ml., falling to 8.6 ,ug./ml. at 24 hours and to 6.5 jig./ml. at 48 hours (Fig. 1) .
Effect of Haemodialysis on Plasma Gentamicin Disappearance Rates.-In the 16 to 27 hours preceding dialysis the level of gentamicin activity in the plasma fell by 0.07 + 0.04 ttg./ml./ hr., and during the 14-hour dialysis period by 0.28 + 0.06 Fig./ ml./hr. (Fig. 2) . The difference in rate of disappearance is statistically significant (P<0.001). This suggests that gentamicin is removed by haemodialysis. It is not possible to measure the amount of gentamicin removed during dialysis, since the dialysate effluent totals 420 1. during a 14-hour dialysis. The concentration of gentamicin in this volume is at the limit of sensitivity of the assay technique.
In-vitro Dialysis of Gentamicin from Plasma.-To determine whether gentamicin in plasma can be dialysed through a cuprophane membrane (PT 150) the following experiment was carried out. A Technicon AutoAnalyzer dialyser unit was set up with a PT 150 membrane. Reconstituted human plasma containing gentamicin and exogenous creatinine was placed in the sample compartment and dialysed against dialysis fluid in the recipient compartment. Both plasma and dialysate were maintained at 40°C., and were recycled at the same rate by means of an AutoAnalyzer proportioning pump. Over the 14-hour period of dialysis the concentration of gentamicin in the plasma fell from 20 to 12 ftg./ml. while that in the dialysis fluid in the recipient compartment rose from zero to 6 jug./ ml. (Fig. 3) . Table) was only 500 mg. From the results presented here it would appear reasonable in patients being dialysed for 14 hours twice a week with a modified Kiil dialyser, cuprophane membranes (PT 150) being used to give 1 mg. of gentamicin per kg. body weight at the end of each dialysis.
There is a notable difference between the peak plasma concentrations of gentamicin in the patients with chronic renal failure compared with the normal subjects. In the two normal subjects peak plasma levels of 5 and 7.5 ttg./ml. were obtained 10 minutes after the intravenous injection of 1.6 mg. of gentamicin per kg. body weight; whereas in the patients with chronic renal failure peak plasma levels of 16 jtg./ml. were obtained. (Pendras, 1964; Pendras and Erickson, 1966; Johnson et al., 1966) . Previous to the present study, two shunt-site infections due to Ps. pyocyanea resulted in the loss of the shunt site within 48 hours, in spite of treatment with colistin sulphate (Colmycin). In the two patients reported here (Cases 1 and 3 Prolonged elevation of plasma gentamicin levels was observed in the patients.
The plasma disappearance rate of gentamicin was significantly increased during haemodialysis by means of a modified Kill dialyser with cuprophane membranes (PT 150). It has been shown that gentamicin is dialysable from plasma with this membrane.
In-patients undergoing twice-weekly haemodialysis on a modified Kiil dialyser with the PT 150 membrane a modified dosage schedule is required; it is suggested that 1 mg. of gentamicin per kg. body weight be given intravenously at the end of each dialysis.
